Recombinant Antibodies

Polatuzumab (anti-CD79b) is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab (anti-CD79b) sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab (anti-CD79b) can

Polatuzumab (anti-CD79b) is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab (anti-CD79b) sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab (anti-CD79b) can

Polatuzumab (anti-CD79b) is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab (anti-CD79b) sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab (anti-CD79b) can

Ponsegromab (anti-GDF15) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab (anti-GDF15) binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated

Ponsegromab (anti-GDF15) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab (anti-GDF15) binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated

Ponsegromab (anti-GDF15) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab (anti-GDF15) binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated

Ponsegromab (anti-GDF15) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab (anti-GDF15) binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab

Praluzatamab (anti-ALCAM) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab (anti-ALCAM) can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab

Ragifilimab (anti-TNFRSF18) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab (anti-TNFRSF18) can be used for advanced or metastatic solid tumors research.Purity&gt95%